Hadlima — CareFirst (Caremark)
Immune checkpoint inhibitor-related toxicity
Initial criteria
- Member has moderate or severe immunotherapy-related inflammatory arthritis AND either inadequate response to corticosteroids or conventional synthetic drug (e.g., methotrexate, sulfasalazine, leflunomide, hydroxychloroquine) OR intolerance or contraindication to corticosteroids and a conventional synthetic drug
Approval duration
12 months